What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's ...

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

With a market cap of $19.5 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and ...

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...

Moderna stock overview Moderna (MRNA) has drawn fresh attention after recent trading left the stock around $49.64, with ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as well as business outlook for 2026 and beyond. It also outlined some expected ...

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the ...

Moderna (MRNA) shares continued to rise in the premarket on Wednesday as analysts argued that the company’s agreement to resolve a patent dispute with Arbutus Biopharma (ABUS) and the Roivant unit ...

The stock soared more than 700% through 2020 and into the first weeks of 2021, and peak vaccine sales reached more than $18 billion for the 2022 full year. But, as demand for coronavirus vaccines ...